全国流感活动迅速上升，中药ETF(159647)涨近1%

Group 1 - The core viewpoint of the news highlights a significant increase in the sales of cold and flu medications due to a rapid rise in flu activity across the country since November, with specific products like Oseltamivir and Mabalosavir seeing sales surges of 237% and 180% respectively [1] - The China Securities Index for Traditional Chinese Medicine (930641) has shown a positive performance, with a 0.87% increase, and notable gains in constituent stocks such as Guangdong Wannianqing (20.02%) and Zhongheng Group (9.70%) [1] - The early onset of the flu season this year is expected to lead to a peak in positive infection rates for flu-related emergency visits, surpassing last year's levels, indicating a potential increase in demand for respiratory infection-related products [1] Group 2 - As of October 31, 2025, the top ten weighted stocks in the China Securities Index for Traditional Chinese Medicine account for 54.92% of the index, with major companies including Yunnan Baiyao, Pian Zai Huang, and Tong Ren Tang [2] - The Traditional Chinese Medicine ETF (159647) closely tracks the performance of the China Securities Index for Traditional Chinese Medicine, which includes publicly listed companies involved in the production and sale of traditional Chinese medicine [1][3]